SANGAMO THERAPEUTICS INC
NASDAQ: SGMO (Sangamo Therapeutics, Inc.)
Kemas kini terakhir: 1 jam lalu0.074
0.00 (0.00%)
| Penutupan Terdahulu | 0.074 |
| Jumlah Dagangan | 28,502,598 |
| Harga / Pendapatan (P/E Ke hadapan) | 0.390 |
| Harga / Jualan (P/S) | 0.690 |
| Harga / Buku (P/B) | 18.13 |
| Julat 52 Minggu |
| Margin Keuntungan | -124.61% |
| Margin Operasi (TTM) | -460.26% |
| EPS Cair (TTM) | -0.360 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 1,238.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 507.05% |
| Nisbah Semasa (MRQ) | 0.760 |
| Aliran Tunai Operasi (OCF TTM) | -44.62 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -20.65 M |
| Pulangan Atas Aset (ROA TTM) | -46.95% |
| Pulangan Atas Ekuiti (ROE TTM) | -257.94% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Sangamo Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | NA |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.0 |
| Purata | -1.00 |
|
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington’s Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.75% |
| % Dimiliki oleh Institusi | 22.78% |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |